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models with inverse probability weighted (IPW) estimation techniques to address those 
challenges in a single model. METHODS: Generalized random effect models were used 
with weights that are calculated as inverse of probability being uncensored. The Gauss-
ian family and log link function were chosen. We applied a test to see if possible censor-
ing bias exists. We also calculated the deviation from the consistent value if standard 
pooled ordinary least squares were used. RESULTS: A total of 4,824 observations were 
used in the analysis. We obtained Medicare claim ﬁ les for the two years following a 
lung-cancer diagnosis. Costs had high kurtosis and skewness. Moreover, 30% of the
cases were censored. Therefore, their annual costs were not observed. The total cost 
of all care is $60K for the two years following a lung-cancer diagnosis and $55K for
incomplete cases. Results signiﬁ cantly diverged from the standard regression model 
(p  0.000). CONCLUSIONS: This paper applies the inverse probability weighted 
estimation to an inception cohort of patients newly diagnosed with lung cancer. Our
ﬁ ndings suggest that the standard regression model yields an inconsistent estimator due
to censoring bias. IPW least square estimation method removes that bias.
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A REVIEW OF THE EVOLUTION OF HEALTH ECONOMIC MODELS OF
SMOKING CESSATION
Fisher MI1, Muston D2, Knight CJ1
1Heron Evidence Development Ltd, Luton, UK, 2Heron Evidence Development Ltd, Stopsley, 
Luton, UK
OBJECTIVES: To review how health economic models of the cost-effectiveness of 
smoking cessation interventions have evolved over the last ten years. METHODS: The 
Medline database was searched via PubMed using the keywords ‘cost-effectiveness
models smoking cessation’. Articles not available or dating before 1998 were excluded.
The abstracts from these results were examined, and relevant studies were selected for 
the review. A bibliographic search was implemented on the selected studies and addi-
tional relevant studies were included. An extraction grid was built to record key 
comparable attributes of each included model as reported. RESULTS: Thirteen studies 
were included and extracted, dating from 1999–2008. The most common model 
design was Markov model simulations of hypothetical patient cohorts given various
interventions (6 studies). Reported cost perspectives have widened over the period: 
since 2004, societal perspectives have been the most common (7/8 studies) whereas
previously direct perspectives were more common (4/5 studies). Prior to 2004, 
3/5 studies were of UK patients whereas since then 4 were for the US, 3 Scandinavia.
The interventions included in the models were initially Nicotine Replacement 
Therapy (NRT) and bupropion (Zyban), but this has widened recently to also include 
varenicline (Champix), which was approved by the FDA in May 2006. It was not
possible to draw clear conclusions as to the values of cost, health outcome and cost-
effectiveness made given the wide variety of study designs, perspectives and countries 
modelled and the small number of studies. CONCLUSIONS: There is wide variety in
the nature of published health economic models of smoking cessation in terms of 
perspective, country and model structure. Some trends have been observed. Markov
models were the most common model design to use for modelling smoking cessation 
cost-effectiveness in the articles we reviewed.
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OBJECTIVES: Inverse propensity scores have been used in observational studies to 
reduce selection bias. To obtain estimates of the main effects, a pseudo data set is
created with weights copies of observations for each subject and analyzed with con-
ventional regression models. Currently variance estimation requires speciﬁ c formulas 
depending on type of outcomes. Our goal is to demonstrate a statistical approach to 
directly obtain the correct estimates of variance of the main effects (usually group
difference in outcomes) in regression models. METHODS: We carried out theoretical 
and simulation studies to show that the variance of the main effects estimated directly 
from regressions is underestimated, and that the type I error rate is higher due to the
inﬂ ated sample size in the pseudo data. We propose to use the stabilized weights to 
directly estimate both the main effect and its variance from conventional regression 
models. RESULTS: We applied the approach to a study examining the effectiveness
of serum potassium monitoring in reducing hyperkalemia-associated adverse events
among 27,362 diabetic patients newly-prescribed a renin-angiotensin-aldosterone
system (RAAS) inhibitor from three HMO Research Network sites. The relative risk
(with monitoring versus without monitoring) and conﬁ dence intervals were 0.52 (0.39, 
0.70) using stabilized weights compared to 0.52 (0.43, 0.64) using typical inverse
propensity scores. The sample size in the pseudo data using the stabilized weights was 
27,312 compared to 54,632 using inverse propensity scores. The sample size in the
pseudo data using the stabilized weights is slightly smaller than the original 27,362
largely due to missing covariates in the propensity score model. CONCLUSIONS: Our 
theoretical, simulation results, and real data example demonstrate that the use of the
stabilized weights in the pseudo data preserves the sample size of original data, pro-
duces correct estimation of the variance of main effect, and maintains an appropriate
type I error rate.
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OBJECTIVES: Cost-effectiveness analysis requires comparison of outcomes in treated 
and untreated populations. Data from randomized clinical trials (RCT) do not provide 
progression rates representative of the general population, while treatment effects in
observational data may be biased due to non-randomization. We developed a novel 
approach for estimating untreated progression rates (controls) by using data from a 
nationally representative patient cohort, as well as RCT estimates. METHODS: We 
used data from the 2000–2005 Sonya Slifka multiple sclerosis (MS) cohort. Disease 
progression was characterized by disability-based disease states and relapses. We 
modeled probabilities of disease state transitions using a ﬁ rst-order annual Markov
model that adjusted for age, gender, disease duration, recent relapse rates, prior states,
and the speciﬁ c disease-modifying therapy (DMT). We developed an iterative multi-
nomial logistic regression algorithm, constraining the effects of DMT to match those 
reported by RCTs. RESULTS: After correcting for the DMT treatment effects and 
other observable risk factors, the probability of disability progression was greater for 
estimates based on all MS patients compared to the estimates based on untreated
individuals only. The 95% conﬁ dence intervals using the entire cohort (including 
treated and untreated individuals) were narrower than the intervals based on the 
subsample of untreated patients. CONCLUSIONS: Our results indicate that 
the untreated patients in our study had lower estimates of disease progression than
the treated patients would have had if they remained untreated. This suggests that
patients who forgo treatment are likely to have milder, slower progressing forms of 
MS. Correcting for treatment effects in a more inclusive group of patients likely pro-
vides a more realistic estimate of disease progression than simply characterizing pro-
gression in an untreated cohort. The use of a broader cohort also improves the
precision of disease progression estimates.
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OBJECTIVES: Classical methods assume that any and all information exists only in 
the data; Empirical Bayes (EB) methods assume, under certain conditions, that an 
informative prior can be calculated from the data. We conducted a simulation to show
the gains achieved by EB over classical methods. METHODS: We assumed that 
exchangeable units of analysis are available from which to calculate prior information. 
A non-parametric prior was estimated as a mixture of normal distributions. The simu-
lation used a two-level, four factor design to generate one-hundred and sixty scenarios.
The factors varied were: (1) the number of units of analysis [25, 50], (2) the sample 
size within each unit of analysis [10 or 25], (3) the number of distributions within the
mixture [2 or 4] and (4) the average effect sizes between the distributions within the 
prior mixture [0.2 and 0.8 standard deviations]. A prior was estimated for each sce-
nario using the EM algorithm across all units of analysis. This prior was combined
with the individual data to estimate posterior means; bootstrap methods were used to
estimate Bayesian conﬁ dence intervals. The Bayesian and Classical results were com-
pared within scenarios on four measures of “goodness”: (1) Absolute difference 
between the “true” mean and the classical and EB estimates, (2) frequency of the EB
mean being closest to the “true” mean, (3) average widths of the EB and classical
intervals, and the actual probability coverage of the estimated intervals. RESULTS:
EB methods were consistently closer in absolute difference and were more frequently 
closer to the “true” mean. EB conﬁ dence intervals were consistently narrower giving 
less uncertainty about the location of the true mean while maintaining the expected
probability coverage. CONCLUSIONS: Using “prior” information based on certain 
assumptions, Empirical Bayes methods provide better estimates of means and conﬁ -
dence intervals compared to classical methods.
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OBJECTIVES: Unlike the literature on estimators for cost data, not much attention
has been paid to the appropriate use of regression estimators for the analysis of health
beneﬁ ts in economic evaluation, i.e. EQ5D and QALYs. We explored the use of Beta 
regression models to address characteristics – such as ceiling effect, truncated distribu-
tion, and heteroschedasticity – typical of any quality of life data. METHODS: We 
developed both a single equation and a two-part Beta regression models (Classical and 
Bayesian), deﬁ ned incremental and marginal effects of covariates on the mean EQ5D, 
and proposed relevant estimators. Using the UK multicentre EVALUATE trial as a
motivating example, we compared results from OLS regression to those obtained from
our Beta-based estimators in terms of estimated mean treatment effect after controlling 
for other covariates. We complemented the case study with a microsimulation exercise. 
RESULTS: The OLS regression ﬁ t the EVALUATE trial EQ5D data as well as any of 
the advanced estimators based on Beta distribution. The estimated treatment effects
were 0.0099 (SE  0.011; 90% CI: 0.022, 0.038) under standard OLS regression 
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and 0.0099 (SE  0.0085; 90% CI: 0.00002, 0.028) under one of the Beta-based esti-
mators, while other Beta-based estimators produced similar results. Our simulation 
results revealed substantial advantage of the Beta-based estimators over OLS when 
the true incremental effect is large, but this advantage dissipates as the incremental
effect gets smaller. CONCLUSIONS: One and two-part Beta regression models can
provide substantial beneﬁ ts, both in terms of bias and efﬁ ciency, over traditional OLS
regression in modeling quality of life data such as EQ5D only when the true incre-
mental effects are large but not when they are small. Our case study conﬁ rms these 
conclusions. Further exploration is required to provide deﬁ nite ranges of incremental
effects where alternative methods are to be preferred.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – 
Patient-Reported Outcomes Studies
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IN EQ-5D USING THE 2002–2003 MEDICAL EXPENDITURE PANEL 
SURVEY (MEPS): A FACETS MODEL APPROACH
Gu NY, Doctor JN
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OBJECTIVES: To evaluate the measurement property of the EQ-5D and to test the 
role of time in affecting the unidimensionality in EQ-5D. METHODS: We extracted 
a sample from the two-year panel (2002–2003) in Medical Expenditure Panel 
Survey (MEPS). Respondents were included if they completed the EQ-5D, were q18 
years of age and were diagnosed with any of the top ten most prevalent chronic condi-
tions using ICD-9-CM (n  1428). Data sets using point-in-time−were constructed 
to analyze the EQ-5D 1) cross-sectional two repeated measures for each respondent. 
For−measures and, 2) longitudinal cross-sectional study, we used Rasch rating scale 
model. For longitudinal analysis, we applied FACETS model by parameterizing 
time with the hypothesis that time plays a signiﬁ cant role in characterizing the unidi-
mensionality of the EQ-5D. Unidimensionality was evaluated using the goodness-
of-ﬁ t of the EQ-5D items to the measurement models. Time severity effect was
examined via item x time interactions to evaluate the measurement invariance pro-
perty of the EQ-5D. RESULTS: Results from both point-in-time measures revealed 
that the mental health item “anxiety/depression” consistently showed misﬁ t in all 
chronic conditions (INFIT/OUTFIT mean square 1.3). Results from longitudinal
analysis demonstrated that including time rendered improved model ﬁ t as unidimen-
sionality of the EQ-5D was achieved in eight out of ten chronic conditions. There was 
signiﬁ cant time severity effects (p  0.05) indicating that the EQ-5D items were 
endorsed differently over time. CONCLUSIONS: Most analysis of health measures 
suggest unidimensionality fails because mental health and physical health items tend
to form different scales. Our ﬁ ndings suggest that time mediates unidimensionality 
and that physical health and mental health are linked through time. As time is essential 
to all chronic disease prognoses, controlling for time in a longitudinal study of health 
measurement is important for proper assessment on the measurement properties of 
health instruments.
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CULTURAL ADAPTATION AND VALIDATION OF A HEATH RELATED
QUALITY OF LIFE QUESTIONNAIRE : FUNCTIONAL OUTCOMES OF
SLEEP QUESTIONNAIRE
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OBJECTIVES: The aim of this study was to determine the reliability and validity of 
the Functional Outcomes of Sleep Questionnaire (FOSQ) for the Turkish population.
METHODS: A total of 200 university students participated. A total of 52% of them 
were men, 48% of them were women. A total of 43% of them lived in the dormitory
and 57% of them lived at the apartments. Data were collected with a sociodemo-
graphic form, FOSQ, and SF-36. Cronbach’s Alfa was used to assess reliability and
factor analysis to assess dimensionality. The SF-36 was used for concurrent validity.
RESULTS: The internal consistency coefﬁ cient (Cronbach’s alpha) of FOSQ was 0.90. 
Factor analysis of the scale revealed that it was composed of three factors with Eigen-
values 2.0, accounting for 57.6% of the total variance. All items of the Turkish FOSQ
had a factor load ranging from 0.413 to 0.731. There was a strong relationship
between Functional Outcomes of Sleep Questionnaire, and SF-36. CONCLUSIONS:
The culturally adapted Functional Outcomes of Sleep Questionnaire had good validity 
and reliability, making it a potentially useful outcome measure in the evaluation of 
insomnia patients in Turkey.
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SHOULD AN SF-10 REPLACE THE SF-12?
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OBJECTIVES: To evaluate the item measurement property of the SF-12v2™ and the 
merits of the physical and mental health component scales (PCS and MCS) using Rasch 
model. METHODS: We extracted a sample from the 2005 Medical Expenditure Panel 
Survey (MEPS). We included respondents who had completed the SF-12v2™, were 
q18 years of age and were diagnosed with any of the top ten most prevalent chronic
conditions using the primary ICD-9-CM (n  5151). Rasch analyses were applied
repeatedly in subgroups on all SF-12v2™ items as a 12-item scale as well as on PCS 
and MCS items separately as two 6-item scales. Items were evaluated using the Rasch 
model ﬁ t statistics to examine 1) whether or not the 12 items measure a unidimen-
sional construct and 2) whether or not PCS items measure a physical health construct 
and MCS items measure a mental health construct. RESULTS: In the 12-item scale, 
the two mental health (MH) items “Have you felt calm and peaceful” and “Have you
felt downhearted and depressed” consistently demonstrating misﬁ t in all subgroups
(inﬁ t/outﬁ t mean square 1.3). By subdividing the PCS and MCS items into two sepa-
rate 6-item scales, all six MCS items had good model ﬁ t including the two MH items.
On the other hand, two PCS items concerning respondents’ general health and bodily
pain showed misﬁ t to the Rasch model. CONCLUSIONS: The SF-12v2™ items do
not form a unidimensional scale as the two MH items did not ﬁ t with other ten items.
However, there are tradeoffs treating PCS and MCS as two distinctive scales as PCS 
items had a reduced ﬁ t. A generic SF-10 for adult population may be a unidimensional
component of the SF-12v2™ and could serve as a brief health survey instrument that 
improves upon the SF-12v2™.
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ARE YOUNG CHILDREN ABLE TO MAKE TRADE-OFFS? A QUALITATIVE
STUDY OF CHILDREN AGED 6 TO 12 YEARS AND THEIR PERCEPTIONS
OF INFLUENZA VACCINATION
Flood E1, Rousculp MD2, Sasane M1, Toback S2, Divino V3, Mahadevia PJ2, Beusterien KM1
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OBJECTIVES: This study explored children’s perceptions of inﬂ uenza and their ability
to make trade-offs among ﬂ u vaccine attributes. METHODS: A qualitative study was 
performed to inform the development of a conceptual model on children’s perceptions 
of inﬂ uenza vaccination. Interviews were conducted by a trained interviewer using an
interview guide. A thematic analysis was conducted to understand perceptions of 
inﬂ uenza and vaccination including inﬂ uenza vaccine attributes such as efﬁ cacy, side
effects, and mode of administration. Study subjects were children aged 6 through 12 
years from the Washington, DC area. RESULTS: A total of 28 children (two males 
and two females per year of age) participated. Parents reported that 75% of the chil-
dren had previously been vaccinated against the inﬂ uenza virus. Knowledge of inﬂ u-
enza varied among children; some were unable to describe inﬂ uenza-illness, while 
others described it as a virus and were able to list speciﬁ c symptoms. Once inﬂ uenza 
was described by the interviewer, all children demonstrated a basic understanding of 
the illness. Efﬁ cacy, risk of side effects and mode of administration were found to 
impact children’s decision to be vaccinated. Children as young as 8-years old were 
able to differentiate low, medium and high risk of side effects and showed the ability
to make rational and consistent tradeoffs between vaccines with differing levels of 
efﬁ cacy, chance of side effects and/or mode of administration. Under certain vaccine 
scenarios, each child was willing to be vaccinated. CONCLUSIONS: Children may
be able to make decisions pertaining to inﬂ uenza vaccination. Young children appear 
to understand the concept of risk and are able to make trade-offs among inﬂ uenza 
vaccine attributes.
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IMPACT OF THE FDA DRAFT GUIDANCE ON PATIENT REPORTED
OUTCOMES (PRO) LABEL CLAIMS FOR APPROVED DRUG PRODUCTS
IN THE US: HAS IT MADE A DIFFERENCE?
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OBJECTIVES: To determine the inﬂ uence of the FDA Draft PRO Guidance on obtain-
ing PRO label claims, for drug products in the US, since its release in February 2006. 
METHODS: Package inserts (indication, clinical trials sections) and medical review
sections from publicly available summary basis of approvals (SBA) for FDA approved
drug products named by the MAPI PROLabels database as having a US-based PRO 
label claim between February 2006 and August 2008 were reviewed. RESULTS: Of 
33 products reviewed, 44 PRO claims were granted. Signs and symptoms (SS) repre-
sented the majority (n  32; 73.7%) of the claims. Within this category, the greatest
number of claims were pain-related (primarily based on a VAS or NRS rating scale)
and more than half of all SS claims were based on a patient diary. After SBA review
for the 24 drug products identiﬁ ed with an available medical review, 13 products were
found to have collected additional PRO within the context of the registration trial 
(reported in the medical review) that did not result in a PRO claim; of these, 6 had
PROs reported to have statistically signiﬁ cant results and 2 of these (Voltaren and 
Fentora) reported clinically meaningful results. Both products were reviewed by the 
same FDA Division of Anesthesia, Analgesia, & Rheumatology (DAAR) and are 
indicated for pain. Of the 33 products reviewed, the Pulmonary and Allergy Products
reviewing division reviewed the most products (nine) and allowed the most PRO
claims (eleven) in the label. Of the 33 products reviewed, SEALD was involved in 4 
product SBA reviews. CONCLUSIONS: Evidence suggests that since the release of the
Draft PRO Guidance, many PRO claims continue to be approved by FDA reviewing 
divisions; however, the reviewing divisions are not always adhering to the current
standards when assessing PRO data for a claim.
